Syndax Pharmaceuticals (STU:1T3) Beginning Cash Position : €271.96 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Beginning Cash Position?

Syndax Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2024 was €271.96 Mil.

Syndax Pharmaceuticals's quarterly Beginning Cash Position declined from Sep. 2023 (€91.35 Mil) to Dec. 2023 (€86.90 Mil) but then increased from Dec. 2023 (€86.90 Mil) to Mar. 2024 (€271.96 Mil).

Syndax Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2021 (€102.09 Mil) to Dec. 2022 (€209.64 Mil) but then declined from Dec. 2022 (€209.64 Mil) to Dec. 2023 (€68.29 Mil).

Syndax Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for Syndax Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Beginning Cash Position Chart

Syndax Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

30.59

20.32

102.09

209.64

68.29

Syndax Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															69.56	53.19	91.35	86.90	271.96

Syndax Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Syndax Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Syndax Pharmaceuticals (STU:1T3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

SNDX:USA

Address

35 Gatehouse Drive, Building D, Floor 3, Waltham, MA, USA, 02451

Website

https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Syndax Pharmaceuticals (STU:1T3) Headlines

No Headlines